Literature DB >> 28973678

L-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway.

Mei Xue1,2, Xu Chen2, Zhija Guo2, Xiaoqian Liu2, Yanping Bi2, Jie Yin1, Haiyan Hu3, Ping Zhu3, Jian Zhuang3, Courtney Cates2, Thomas Rousselle2, Ji Li2.   

Abstract

We aim to investigate the cardioprotective effects of L-carnitine (LC) on cardiac function during ischemia and reperfusion (I/R) and contractile function of single cardiomyocyte. C57BL/6 J mice were randomly assigned to 5 groups: sham group; vehicle group, LC preconditioning group, LC preconditioning + LY294002 (a PI3K/Akt signaling pathway inhibitor) group (LC + LY), and LY294002 group (LY). The sham group was exposed to the open heart operation but not I/R, the other groups received 45 min ischemia/48 h reperfusion. At the end of reperfusion, echocardiography was performed on every mouse. In order to determine whether LC's cardioprotection could act directly at the level of cardiomyocytes, we also tested its effects on isolated cardiomyocytes under hypoxia condition. The expressions of p-PI3K, PI3K, Akt, p-Akt, Bax and Bcl-2 proteins were detected by immunoblotting. The results showed that LC preconditioning remarkably improved cardiac function after I/R, but the cardioprotective effect of LC was significantly weakened after the application of LY294002. We also found that LC could directly improve the contractile function of cardiomyocytes under hypoxia condition. The immunoblotting results showed that LC administration restrained myocardial apoptosis as evidenced by decreasing the level of Bax expression, increasing the levels of phosphorylation of Akt, PI3K, and Bcl-2 protein expression, but these were blocked by LYC94002. Thus, the cardioprotective effects of LC against myocardial ischemic damage and its effect on single cardiomyocyte under hypoxia may be associated with the PI3K/Akt signaling pathway.
© The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Akt; L-carnitine; myocardial ischemia reperfusion

Mesh:

Substances:

Year:  2017        PMID: 28973678      PMCID: PMC5837463          DOI: 10.1093/toxsci/kfx193

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  45 in total

Review 1.  Pathobiology of ischaemic stroke: an integrated view.

Authors:  U Dirnagl; C Iadecola; M A Moskowitz
Journal:  Trends Neurosci       Date:  1999-09       Impact factor: 13.837

2.  Effect of L-carnitine on cardiomyocyte apoptosis and cardiac function in patients undergoing heart valve replacement operation.

Authors:  Daokang Xiang; Zongquan Sun; Jiahong Xia; Nianguo Dong; Xinling Du; Xinzhong Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation.

Authors:  R Schulz; B D Guth; K Pieper; C Martin; G Heusch
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

4.  Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway.

Authors:  Xingshun Xu; Chu Chang Chua; Jinping Gao; Kao-Wei Chua; Hong Wang; Ronald C Hamdy; Balvin H L Chua
Journal:  Brain Res       Date:  2008-06-16       Impact factor: 3.252

5.  Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress.

Authors:  Chao Tong; Alex Morrison; Samantha Mattison; Su Qian; Mark Bryniarski; Bethany Rankin; Jun Wang; D Paul Thomas; Ji Li
Journal:  FASEB J       Date:  2012-09-28       Impact factor: 5.191

6.  Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition.

Authors:  T Furuno; T Kanno; K Arita; M Asami; T Utsumi; Y Doi; M Inoue; K Utsumi
Journal:  Biochem Pharmacol       Date:  2001-10-15       Impact factor: 5.858

7.  Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss.

Authors:  Gilda M Kalinec; Martin E Fernandez-Zapico; Raul Urrutia; Nora Esteban-Cruciani; Shanping Chen; Federico Kalinec
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-20       Impact factor: 11.205

Review 8.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

9.  L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes.

Authors:  Hung-Hsin Chao; Ju-Chi Liu; Hong-Jye Hong; Jia-wei Lin; Cheng-Hsien Chen; Tzu-Hurng Cheng
Journal:  Int J Cardiol       Date:  2009-06-23       Impact factor: 4.164

10.  Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation.

Authors:  J Ross
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more
  3 in total

1.  Dichloroacetate Ameliorates Cardiac Dysfunction Caused by Ischemic Insults Through AMPK Signal Pathway-Not Only Shifts Metabolism.

Authors:  Xuan Li; Jia Liu; Haiyan Hu; Shaoxin Lu; Qingguo Lu; Nanhu Quan; Thomas Rousselle; Mulchand S Patel; Ji Li
Journal:  Toxicol Sci       Date:  2019-02-01       Impact factor: 4.849

2.  L-Carnitine: An Antioxidant Remedy for the Survival of Cardiomyocytes under Hyperglycemic Condition.

Authors:  Fernanda Vacante; Pamela Senesi; Anna Montesano; Alice Frigerio; Livio Luzi; Ileana Terruzzi
Journal:  J Diabetes Res       Date:  2018-12-09       Impact factor: 4.011

3.  L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.

Authors:  Hai Yan Zhao; Hui Ying Li; Jian Jin; Ji Zhe Jin; Long Ye Zhang; Mei Ying Xuan; Xue Mei Jin; Yu Ji Jiang; Hai Lan Zheng; Ying Shun Jin; Yong Jie Jin; Bum Soon Choi; Chul Woo Yang; Shang Guo Piao; Can Li
Journal:  Korean J Intern Med       Date:  2020-09-18       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.